GlassScriptPhysician profile
Sarah Alaimo
NPI 1245359314
$12,938.55
in general payments reported to CMS, 2019-2025
51 companies · $3,299 in 2025
The $3,299 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,568 · 2022: $1,861 · 2023: $2,538 · 2024: $2,674 · 2025: $3,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,110 · Consulting Fee: $300 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,110.24 |
| Consulting Fee | $300.00 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,651.10 | 2021-2025 | Ubrelvy, Botox, Duopa |
| Pfizer INC. | $1,064.25 | 2023-2025 | |
| Lilly USA, LLC | $867.86 | 2021-2025 | Kisunla, Amyvid, Reyvow |
| Biogen, INC. | $761.17 | 2021-2025 | Tysabri, Vumerity |
| Alexion Pharmaceuticals, INC. | $580.61 | 2021-2024 | Ultomiris |
| Argenx US, INC. | $475.20 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $473.33 | 2021-2025 | Aimovig, Uplizna |
| Eisai INC. | $430.40 | 2023-2025 | |
| Lundbeck LLC | $395.97 | 2022-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $362.45 | 2021-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $354.55 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $317.74 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Genzyme Corporation | $313.47 | 2021-2025 | |
| Kyowa Kirin, INC. | $275.73 | 2021-2025 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $270.77 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Alaimo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.